NASDAQ
2.89USD
+0.05 (+1.76%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
18.5M
P/E
—
EPS
—
Beta
0.44
52W range
2.07-31.914
Day range
2.81–2.95
Open
2.95
Prev close
2.84
Volume
50K
Avg volume
266.2K
Dividend
0.00
IPO
2018-06-08
https://www.globenewswire.com/news-release/2026/07/30/3335726/0/en/Quantum-BioPharma-Announces-Closing-of-Debt-Settlement.html · 7/30/2026+0.30
https://www.globenewswire.com/news-release/2026/06/02/3305044/0/en/Quantum-BioPharma-Engages-Stocks-news-For-Investor-Relations-Marketing-Services-And-Lead-Generation-Campaigns.html · 6/2/2026+0.30
https://www.globenewswire.com/news-release/2026/06/01/3304799/0/en/Quantum-BioPharma-Provides-Corporate-Update.html · 6/1/2026-0.80
https://www.globenewswire.com/news-release/2026/05/18/3296317/0/en/quantum-biopharma-reaches-key-midpoint-milestone-in-groundbreaking-imaging-study-with-massachusetts-general-hospital.html · 5/18/2026+0.80
https://www.globenewswire.com/news-release/2026/04/27/3282159/0/en/Quantum-BioPharma-Provides-Corporate-Update.html · 4/27/2026
https://www.defenseworld.net/2026/04/19/comparing-quantum-biopharma-nasdaqqntm-arcutis-biotherapeutics-nasdaqarqt.html · 4/19/2026-0.60
https://www.defenseworld.net/2026/04/04/cannabis-stocks-to-watch-today-april-2nd.html · 4/4/2026+0.20
https://www.globenewswire.com/news-release/2026/03/10/3253449/0/en/Quantum-BioPharma-Provides-Corporate-Update.html · 3/10/2026+0.30
https://www.globenewswire.com/news-release/2026/02/17/3239663/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Quantum-Biopharma-Ltd-Investors.html · 2/17/2026-1.00
https://www.globenewswire.com/news-release/2026/02/17/3239436/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Quantum-Corporation-Investors.html · 2/17/2026-1.00
https://www.globenewswire.com/news-release/2026/02/09/3234778/9788/en/Bronstein-Gewirtz-Grossman-LLC-Urges-Quantum-Biopharma-Ltd-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm.html · 2/9/2026-0.50
https://www.globenewswire.com/news-release/2026/02/05/3233364/9788/en/Bronstein-Gewirtz-Grossman-LLC-Urges-Quantum-Biopharma-Ltd-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm.html · 2/5/2026-0.40
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
